These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 4459738)

  • 21. An effective low-dose mitomycin regimen for hormonal- and chemotherapy-refractory patients with metastatic breast cancer.
    Creech RH; Catalano RB; Shah MK; Dayal H
    Cancer; 1983 Mar; 51(6):1034-40. PubMed ID: 6821868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First-line and salvage therapy of metastatic breast cancer with mitomycin/vinblastine.
    Sedlacek SM
    Oncology; 1993 Apr; 50 Suppl 1():16-21. PubMed ID: 8483557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.
    Nabholtz JM; Thuerlimann B; Bezwoda WR; Melnychuk D; Deschênes L; Douma J; Vandenberg TA; Rapoport B; Rosso R; Trillet-Lenoir V; Drbal J; Aapro MS; Alaki M; Murawsky M; Riva A
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):25-30. PubMed ID: 9364538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II evaluation of piperazinedione in metastatic breast carcinoma.
    Palmer RL; Samal BA; Vaughn CB; Tranum BL
    Cancer Treat Rep; 1977 Dec; 61(9):1711-2. PubMed ID: 340035
    [No Abstract]   [Full Text] [Related]  

  • 25. An evaluation of hexamethylmelamine, cis-diamminedichloroplatinum, and mitomycin-C in advanced breast cancer. A pilot study of the Southeastern Cancer Study Group.
    Lawson D; Moore M; Smalley R
    Cancer Clin Trials; 1980; 3(4):293-6. PubMed ID: 6775826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mitomycin-C in the therapy of far-advanced malignant tumors.
    Manheimer LH; Vital J
    Cancer; 1966 Feb; 19(2):207-12. PubMed ID: 5905463
    [No Abstract]   [Full Text] [Related]  

  • 27. Phase II study of 7-N-(p-hydroxyphenyl)-mitomycin C (KW2083) in patients with advanced non-small cell carcinoma of the lung and metastatic pulmonary tumors.
    Shinkai T; Saijo N; Tominaga K; Eguchi K; Shimizu E; Sasaki Y; Fujita J; Futami H; Hoshi A
    Jpn J Clin Oncol; 1985 Mar; 15(1):61-5. PubMed ID: 3981815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II study of CCNU (NSC-79037) in the treatment of advanced gastrointestinal cancer.
    Klaassen DJ; Rapp E
    Cancer Chemother Rep; 1974; 58(5 Pt 1):667-9. PubMed ID: 4426046
    [No Abstract]   [Full Text] [Related]  

  • 29. Combination chemotherapy in gastrointestinal cancer.
    Reitemeier RJ; Moertel CG; Hahn RG
    Cancer Res; 1970 May; 30(5):1425-8. PubMed ID: 4246651
    [No Abstract]   [Full Text] [Related]  

  • 30. Phase I study of chromomycin A (NSC-58514).
    Kovach JS; Moertel CG; Ahmann DL; Hahn RG; Schutt AJ; Donadio JV
    Cancer Chemother Rep; 1973; 57(3):341-7. PubMed ID: 4751258
    [No Abstract]   [Full Text] [Related]  

  • 31. Phase I-II study of high-dose mitomycin with autologous bone marrow transplantation in refractory metastatic breast cancer.
    Tannir N; Spitzer G; Dicke K; Schell F; DiStefano A; Blumenschein G
    Cancer Treat Rep; 1984 May; 68(5):805-6. PubMed ID: 6426793
    [No Abstract]   [Full Text] [Related]  

  • 32. Phase II study of profiromycin vs mitomycin-C utilizing acute intermittent schedules.
    Baker LH; Izbicki RM; Vaitkevicius VK
    Med Pediatr Oncol; 1976; 2(2):207-13. PubMed ID: 958162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytosine arabinoside (NSC 63878) toxicity and antitumor acitivity in human solid tumors.
    Davis HL; Rochlin DB; Weiss AJ; Wilson WL; Andrews NC; Madden R; Sedransk N
    Oncology; 1974; 29(3):190-200. PubMed ID: 4412696
    [No Abstract]   [Full Text] [Related]  

  • 34. Mitomycin C therapy in superficial bladder cancer.
    Denis L; Keuppens F; Hendrickx G
    Prog Clin Biol Res; 1985; 185B():113-22. PubMed ID: 3929269
    [No Abstract]   [Full Text] [Related]  

  • 35. Phase II study of hexamethylmelamine alone and in combination with mitomycin C and vincristine in advanced breast carcinoma.
    Legha SS; Buzdar AU; Hortobagyi GN; DiStefano A; Wiseman CL; Yap HY; Blumenschein GR; Bodey GP
    Cancer Treat Rep; 1979; 63(11-12):2053-6. PubMed ID: 118805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer.
    Dieras V; Marty M; Tubiana N; Corette L; Morvan F; Serin D; Mignot L; Chazard M; Garet F; Onetto N
    Semin Oncol; 1995 Aug; 22(4 Suppl 8):33-9. PubMed ID: 7638640
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination chemotherapy with BCNU, vincristine, mitomycin-C and prednisone in refractory breast carcinoma. A pilot study.
    DiBella NJ; Garfield D; Fink K; Anderson P; Speer J; Murphy J
    Oncology; 1984; 41(1):1-3. PubMed ID: 6422372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mitomycin C, vincristine, and bleomycin therapy for advanced cervical cancer.
    Baker LH; Opipari MI; Wilson H; Bottomley R; Coltman CA
    Obstet Gynecol; 1978 Aug; 52(2):146-50. PubMed ID: 79991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II evaluation of vindesine in patients with advanced breast cancer.
    Currie VE; Camacho F; Wittes R; Young C
    Cancer Treat Rep; 1980; 64(4-5):693-95. PubMed ID: 7427954
    [No Abstract]   [Full Text] [Related]  

  • 40. Long duration of response with vindesine-mitoxantrone-mitomycin (VMMc) combination chemotherapy in metastatic breast cancer: a pilot phase II study.
    Belpomme D; Heritier F; Gisselbrecht C; Marty M; Michaud G; Le Rol A; Cour V; George C; Maral J
    Cancer Treat Rep; 1987 Sep; 71(9):845-7. PubMed ID: 3621218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.